Screener / SEC EDGAR /CIK 0000037785 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Materials · Chemicals & Allied Products

FMC Corp FMC

Compare with peers Embed
FY2025 at a glance

Sales down 18.3%, free cash flow down to -$102.5M

XBRL, from each 10-K
RevenueStatements
$3.5B from $4.2B in FY2024
FY2016FY2025
Net incomeStatements
-$2.2B from $341.1M in FY2024
FY2016FY2025
Free cash flowStatements
-$102.5M from $668.8M in FY2024
FY2016FY2025
EPS (diluted)Statements
$-17.88 from $2.72 in FY2024
FY2016FY2025
Operating marginStatements
-47.0% from 11.9% in FY2024
FY2016FY2025
Total debtStatements
$4.1B from $3.4B in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (40)
EPS (ttm)
-33.51
Sales (ttm)
2.8B
Net income (ttm)
-4.3B
Sales growth
-18.3%
EPS growth
to a loss
Sales Q/Q
-80.5%
Free cash flow
370.1M
Gross margin
22.0%
Oper. margin
-97.0%
Net margin
-151.2%
FCF margin
13.1%
ROE
n/m
R&D / sales
7.7%
Dividend
1.82
Debt/Eq
n/m
Curr. ratio
1.66
Cash
735.8M
Op. cash flow (ttm)
425.8M
EBITDA
-1.5B
EBITDA margin
-42.0%
Net debt
3.4B
Quick ratio
1.22
Interest cover
-6.80
FCF after stock pay
-126.5M
Goodwill / assets
0.0%
Oper. margin low 5y
-47.0%
Stock pay / sales
0.7%
Shares out.
155.6M
Shares Y/Y
-0.2%
Book / share
-0.12
Cash / share
4.73
Sales / share
18.10
Asset turnover
0.36
Inventory turns
1.79
Days sales out.
217
Sales 3Y CAGR
-15.8%
Sales 5Y CAGR
-5.7%
Employees
5,500
Sales / employee
512K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 3.5B +3.5% a year Net income -2.2B
FY2016 revenue 2.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000037785-19-000039 FY2016 net income 209.1M · NetIncomeLoss, 0000037785-19-000039 2.5B FY2016 FY2017 revenue 2.9B · Revenues, 0000037785-19-000039 FY2017 net income 535.8M · NetIncomeLoss, 0000037785-20-000035 2.9B FY2017 FY2018 revenue 4.7B · Revenues, 0000037785-19-000039 FY2018 net income 502.1M · NetIncomeLoss, 0000037785-21-000024 4.7B FY2018 FY2019 revenue 4.6B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000037785-22-000025 FY2019 net income 477.4M · NetIncomeLoss, 0000037785-22-000025 4.6B FY2019 FY2020 revenue 4.6B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000037785-23-000019 FY2020 net income 552.4M · NetIncomeLoss, 0000037785-23-000019 4.6B FY2020 FY2021 revenue 5.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000037785-24-000033 FY2021 net income 739.6M · NetIncomeLoss, 0000037785-24-000033 5.0B FY2021 FY2022 revenue 5.8B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000037785-25-000030 FY2022 net income 736.5M · NetIncomeLoss, 0000037785-25-000030 5.8B FY2022 FY2023 revenue 4.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000037785-26-000041 FY2023 net income 1.3B · NetIncomeLoss, 0000037785-26-000041 4.5B FY2023 FY2024 revenue 4.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000037785-26-000041 FY2024 net income 341.1M · NetIncomeLoss, 0000037785-26-000041 4.2B FY2024 FY2025 revenue 3.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000037785-26-000041 FY2025 net income -2.2B · NetIncomeLoss, 0000037785-26-000041 3.5B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share +1.7% a year FY2015 $13.95 to FY2025 $16.55, 10 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 -$17.88$16.55-$0.82
Dec 31, 2024 $2.72$35.80$5.34
Dec 31, 2023 $10.53$35.14-$3.46
Dec 31, 2022 $5.81$26.66$4.09
Dec 31, 2021 $5.73$24.19$6.18
Dec 31, 2020 $4.23$22.68$5.13
Dec 31, 2019 $3.62$19.18$3.50
Dec 31, 2018 $3.69$22.97$2.06
Dec 31, 2017 $3.99$19.98$1.44
Dec 31, 2016 $1.56$14.55$2.06
Dec 31, 2015 $3.66$13.95-$3.92

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $5.0B
  • − All liabilities (total assets less equity) $7.6B
  • = Net current asset value -$2.7B
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $2.1B
  • − Other intangible assets $2.4B
  • = Tangible book value -$290.3M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result. This company does not tag total liabilities, so total assets less equity is used (it includes any non-controlling interest).

FMC against Materials peers

Among the 88 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
-2.2%+10.5%
-18.3%84th of 85 · median +3.6%
Net margin
2.1%12.0%
-151.2%84th of 85 · median 6.8%
Free cash flow margin
3.2%12.5%
13.1%19th of 83 · median 7.4%
FMC and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
FMC FMC Corp$2.8B -18.3%22.0%-151.2%-13.1%-
CRS Carpenter Technology Corp$3.2B +8.6%31.2%17.9%26.1%10.7%0.32
BDC Belden Inc.$3.1B +10.3%36.8%5.6%12.7%7.3%2.19
NEU Newmarket Corp$2.8B -2.2%31.7%16.5%23.7%13.8%0.43
SKY Champion Homes, Inc.$2.7B +7.3%25.5%6.8%11.8%8.5%0.01
LPX Louisiana-Pacific Corp$2.5B -7.9%17.2%2.7%3.9%1.2%0.20
All 88 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by product

From $5.0B of sales to $739.6M of profit FY2021

Revenue to Gross profit: $2.2BRevenue to Cost of revenue: $2.9BGross profit to Operating profit: $1.0BGross profit to Operating expenses: $1.1BOperating profit to Net profit: $739.6MOperating profit to Tax & other: $294.9MOperating expenses to R&D: $304.7MOperating expenses to Sales, admin & other: $822.1M Revenue: $5.0B REVENUE $5.0B +9% Y/Y Gross profit: $2.2B · 43% margin GROSS PROFIT $2.2B 43% margin · +6% Y/Y Cost of revenue: $2.9B · 57% of revenue COST OF REVENUE $2.9B 57% of revenue Operating profit: $1.0B · 21% margin OPERATING PROFIT $1.0B 21% margin · +15% Y/Y Operating expenses: $1.1B · 22% of revenue OPERATING EXPENSES $1.1B 22% of revenue Net profit: $739.6M · 15% margin NET PROFIT $739.6M 15% margin · +34% Y/Y Tax & other: $294.9M · 6% of revenue TAX & OTHER $294.9M 6% of revenue R&D: $304.7M · 6% of revenue R&D $304.7M 6% of revenue Sales, admin & other: $822.1M · 16% of revenue SALES, ADMIN & OTHER $822.1M 16% of revenue

From $5.8B of sales to $736.5M of profit FY2022

  • Insecticides $3.3B
  • Herbicides $1.7B
  • Fungicides $383.9M
  • Plant Health $234.1M
  • Other $186.1M
Revenue to Gross profit: $2.3BRevenue to Cost of revenue: $3.5BGross profit to Operating profit: $1.1BGross profit to Operating expenses: $1.2BOperating profit to Net profit: $736.5MOperating profit to Tax & other: $407.8MOperating expenses to R&D: $314.2MOperating expenses to Sales, admin & other: $868.3M Revenue: $5.8B REVENUE $5.8B +15% Y/Y Gross profit: $2.3B · 40% margin GROSS PROFIT $2.3B 40% margin · +8% Y/Y Cost of revenue: $3.5B · 60% of revenue COST OF REVENUE $3.5B 60% of revenue Operating profit: $1.1B · 20% margin OPERATING PROFIT $1.1B 20% margin · +11% Y/Y Operating expenses: $1.2B · 20% of revenue OPERATING EXPENSES $1.2B 20% of revenue Net profit: $736.5M · 13% margin NET PROFIT $736.5M 13% margin · +0% Y/Y Tax & other: $407.8M · 7% of revenue TAX & OTHER $407.8M 7% of revenue R&D: $314.2M · 5% of revenue R&D $314.2M 5% of revenue Sales, admin & other: $868.3M · 15% of revenue SALES, ADMIN & OTHER $868.3M 15% of revenue

From $4.5B of sales to $1.3B of profit FY2023

  • Insecticides $2.6B
  • Herbicides $1.3B
  • Fungicides $317.6M
  • Plant Health $186.9M
  • Other $64.5M
Revenue to Gross profit: $1.8BRevenue to Cost of revenue: $2.7BGross profit to Operating profit: $555.6MGross profit to Operating expenses: $1.3BOperating profit to Net profit: $555.6MOther income to Net profit: $765.9MOperating expenses to R&D: $328.8MOperating expenses to Sales, admin & other: $946.6M Revenue: $4.5B REVENUE $4.5B −23% Y/Y Gross profit: $1.8B · 41% margin GROSS PROFIT $1.8B 41% margin · −21% Y/Y Cost of revenue: $2.7B · 59% of revenue COST OF REVENUE $2.7B 59% of revenue Operating profit: $555.6M · 12% margin OPERATING PROFIT $555.6M 12% margin · −51% Y/Y Other income: $765.9M · 17% of revenue OTHER INCOME $765.9M 17% of revenue Operating expenses: $1.3B · 28% of revenue OPERATING EXPENSES $1.3B 28% of revenue Net profit: $1.3B · 29% margin NET PROFIT $1.3B 29% margin · +79% Y/Y R&D: $328.8M · 7% of revenue R&D $328.8M 7% of revenue Sales, admin & other: $946.6M · 21% of revenue SALES, ADMIN & OTHER $946.6M 21% of revenue

From $4.2B of sales to $341.1M of profit FY2024

  • Insecticides $2.4B
  • Herbicides $1.3B
  • Fungicides $352.5M
  • Plant Health $200.5M
  • Other $34.7M
Revenue to Gross profit: $1.6BRevenue to Cost of revenue: $2.6BGross profit to Operating profit: $506.5MGross profit to Operating expenses: $1.1BOperating profit to Net profit: $341.1MOperating profit to Interest, tax, other: $165.4MOperating expenses to R&D: $278.0MOperating expenses to Sales, admin & other: $864.4M Revenue: $4.2B REVENUE $4.2B −5% Y/Y Gross profit: $1.6B · 39% margin GROSS PROFIT $1.6B 39% margin · −10% Y/Y Cost of revenue: $2.6B · 61% of revenue COST OF REVENUE $2.6B 61% of revenue Operating profit: $506.5M · 12% margin OPERATING PROFIT $506.5M 12% margin · −9% Y/Y Operating expenses: $1.1B · 27% of revenue OPERATING EXPENSES $1.1B 27% of revenue Net profit: $341.1M · 8% margin NET PROFIT $341.1M 8% margin · −74% Y/Y Interest, tax, other: $165.4M · 4% of revenue INTEREST, TAX, OTHER $165.4M 4% of revenue R&D: $278.0M · 7% of revenue R&D $278.0M 7% of revenue Sales, admin & other: $864.4M · 20% of revenue SALES, ADMIN & OTHER $864.4M 20% of revenue

Where each $100 of sales went

FY2021
FY2022
FY2023
FY2024
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax & other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity -108.1% FY2020: 18.7% net income ÷ equity
Net margin -64.6% FY2020: 11.9% profit per $ of sales: -2.2B ÷ 3.5B
Asset turnover 0.36× FY2020: 0.46× sales per $ of assets: 3.5B ÷ 9.7B
Leverage 4.68× FY2020: 3.44× assets per $ of equity: 9.7B ÷ 2.1B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -151.2% vs 6.8%
  • Gross margin down over 5 years
    44.1% → 37.0%
  • A profit in 9 of 10 years
Net margin, FY2016 to FY2025: 8.2% to -64.6%

Balance sheet

  • Interest covered less than 5 times
    Operating income is -6.8× interest expense
  • Equity below zero
    Debt $4.2B, equity −$19.4M
  • Current assets cover current liabilities
    Current ratio 1.66
  • Net debt over 3 years of free cash flow
    $3.4B net debt, 9.3 years
Debt / equity at each year end, FY2016 to FY2025: 0.92 to 1.97

Cash and shareholders

  • Free cash flow positive in 8 of 10 years
    −$102.5M last year
  • Share count down over 5 years
    −4.2%
  • Dividend per share up over 5 years
    $1.80 → $1.82
Free cash flow, FY2016 to FY2025: 277.7M to -102.5M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$3.4B of principal due, schedule of Dec 31, 2025

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Contract liabilities

Paid in advance $267.8M cash received before delivery, not yet recognized as revenue, Sep 30, 2026

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

FMC's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue3.5B
FY2016: 2.5BFY2017: 2.9BFY2018: 4.7BFY2019: 4.6BFY2020: 4.6BFY2021: 5.0BFY2022: 5.8BFY2023: 4.5BFY2024: 4.2BFY2025: 3.5B FY2017FY2019FY2021FY2023FY2025
Net income-2.2B
FY2016: 209.1MFY2017: 535.8MFY2018: 502.1MFY2019: 477.4MFY2020: 552.4MFY2021: 739.6MFY2022: 736.5MFY2023: 1.3BFY2024: 341.1MFY2025: -2.2B FY2017FY2019FY2021FY2023FY2025
Free cash flow-102.5M
FY2016: 277.7MFY2017: 193.7MFY2018: 279.7MFY2019: 461.7MFY2020: 669.6MFY2021: 798.5MFY2022: 517.7MFY2023: -434.2MFY2024: 668.8MFY2025: -102.5M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay-126.5M
FY2016: 257.5MFY2017: 172.6MFY2018: 257.2MFY2019: 436.1MFY2020: 650.7MFY2021: 780.7MFY2022: 493.5MFY2023: -460.1MFY2024: 645.0MFY2025: -126.5M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)-17.88
FY2016: 1.56FY2017: 3.99FY2018: 3.69FY2019: 3.62FY2020: 4.23FY2021: 5.73FY2022: 5.81FY2023: 10.53FY2024: 2.72FY2025: -17.88 FY2017FY2019FY2021FY2023FY2025
Dividend per share1.82
FY2016: 0.66FY2017: 0.66FY2018: 0.90FY2019: 1.64FY2020: 1.80FY2021: 1.96FY2022: 2.17FY2023: 2.32FY2024: 2.32FY2025: 1.82 FY2017FY2019FY2021FY2023FY2025
Diluted shares125.2M
FY2016: 134.5MFY2017: 134.3MFY2018: 135.9MFY2019: 132.0MFY2020: 130.6MFY2021: 129.1MFY2022: 126.7MFY2023: 125.5MFY2024: 125.4MFY2025: 125.2M FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Insecticides 1.6B45.4% -33.9%
Herbicides 1.2B36.0% -2.6%
Fungicides 362.8M10.5% +2.9%
Plant Health 190.9M5.5% -4.8%
Other 94.1M2.7% +171%

10-K 0000037785-26-000041, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
Latin America 1.4B39.0% -2.7%
Brazil 1.1B32.2% +3.3%
North America 1.1B31.8% -6.1%
U.S. 923.1M26.6% -8.0%
Europe, Middle East & Africa 871.5M25.1% +4.4%
Asia 142.3M4.1% -83.2%

10-K 0000037785-26-000041, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue2.5B2.9B4.7B4.6B4.6B5.0B5.8B4.5B4.2B3.5B
Cost of revenue1.6B1.6B2.4B2.5B2.6B2.9B3.5B2.7B2.6B2.2B
Gross profit931.2M951.8M1.9B2.1B2.0B2.2B2.3B1.8B1.6B1.3B
R&D134.5M138.4M287.7M298.1M287.9M304.7M314.2M328.8M278.0M266.1M
SG&A435.1M581.7M790.0M792.9M729.7M714.1M775.2M734.3M644.6M684.9M
Operating income266.6M158.5M740.9M821.6M896.9M1.0B1.1B555.6M506.5M-1.6B
Interest expense63.5M80.0M134.5M160.4M151.3M131.1M151.8M237.2M235.8M239.6M
Pretax income180.8M95.8M608.4M655.0M731.0M897.8M983.9M300.2M252.5M-1.9B
Income tax50.1M228.9M70.8M111.5M151.2M92.5M145.2M-1.1B-150.9M314.2M
Net income209.1M535.8M502.1M477.4M552.4M739.6M736.5M1.3B341.1M-2.2B
EPS (diluted)1.563.993.693.624.235.735.8110.532.72-17.88
Diluted shares134.5M134.3M135.9M132.0M130.6M129.1M126.7M125.5M125.4M125.2M
Depreciation & amortization100.6M97.8M150.2M150.1M162.7M170.9M169.4M184.3M176.3M173.6M
EBITDA367.2M256.3M891.1M971.7M1.1B1.2B1.3B739.9M682.8M-1.5B
Gross margin36.7%33.1%39.8%45.2%44.1%42.8%40.1%40.8%38.8%37.0%
Operating margin10.5%5.5%15.7%17.8%19.3%20.5%19.7%12.4%11.9%-47.0%
Net margin8.2%18.6%10.6%10.4%11.9%14.7%12.7%29.5%8.0%-64.6%
Revenue growth+1.9%+13.4%+64.2%-2.5%+0.7%+8.7%+15.0%-22.7%-5.4%-18.3%
EPS growth-57.4%+156%-7.5%-1.9%+16.9%+35.5%+1.4%+81.2%-74.2%to a loss

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)20.2M21.1M22.5M25.6M18.9M17.8M24.2M25.9M23.8M24.0M
Stock-based pay / revenue0.8%0.7%0.5%0.6%0.4%0.4%0.4%0.6%0.6%0.7%
Operating lease cost---41.3M39.5M33.9M32.9M33.2M36.1M34.5M
Operating lease cash paid---42.3M40.8M33.1M33.9M35.9M41.2M37.9M
Right-of-use assets---164.7M147.3M135.2M123.8M121.8M110.4M104.9M
Operating lease liabilities---194.7M176.7M163.5M150.6M147.6M130.6M123.9M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/FMC/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.